22nd Century Group Inc.

22nd Century Group Inc.

22nd Century is a plant biotechnology company with an important mission: To Reduce the Harm Caused by Smoking.
1d 5d 1m 6m 1y Max

22nd Century Group Inc. News

14 Jun

Can We See Significant Insider Ownership On The 22nd Century Group, Inc. (NYSEMKT:XXII) Share Register?

The big shareholder groups in 22nd Century Group, Inc. (NYSEMKT:XXII) have power over the company. Large companies...

14 Jun

22nd Century Group Appoints Michael J. Zercher as Chief Operating Officer

22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco, and hemp/cannabis research, announced...

14 Jun

22nd Century Group names COO

22nd Century Group ( XXII -1.7% ) announces the appointment of Michael Zercher as the company's chief operating officer. More news on: 22nd Century Group, Inc., Consumer stocks news, Read more...

09 May

Edited Transcript of XXII earnings conference call or presentation 8-May-19 8:00pm GMT

Q1 2019 22nd Century Group Inc Earnings Call

08 May

22nd Century: 1Q Earnings Snapshot

The Williamsville, New York-based company said it had a loss of 2 cents per share. The plant biotechnology company posted revenue of $6.3 million in the period. The company's shares closed at $2.21. A...

07 May

22nd Century Files 2019 First Quarter Report and Announces Conference Call to Provide Business Update

22nd Centurys proposed VLN cigarettes continue to fall squarely within the nicotine range that public health officials anticipate will be mandated by the FDA. Companys financial position remains strong;...

06 May

7 Marijuana Stocks That Are Bleeding Cash

You may find it surprising, but the Post Office, the Atlanta Hawks and these seven marijuana stocks all have something in common. At first glance, you may think they have nothing to do with each other....

01 May

22nd Century Group Announces FDA Inspection For Its Pre-Market Tobacco Application

22nd Century Group Inc. (NYSEAMERICAN:XXII) has announced that last week the FDA carried out a comprehensive inspection of its North Carolina manufacturing facility in line with the review of the company's...

30 Apr

22nd Century’s Pre-Market Tobacco Application for VLN™ Cigarettes Advances with Completed FDA Inspection

22nd Century Group, Inc. (NYSE American:XXII), a plant biotechnology company that is a world leader in tobacco harm reduction, Very Low Nicotine Content tobacco, and hemp/cannabis research, announced...

30 Apr

22nd Century's Pre-Market Tobacco Application for VLN(TM) Cigarettes Advances with Completed FDA Inspection

FDA Inspection is an important milestone for 22nd Centurys VLN Cigarettes 22nd Century Group, Inc. (NYSE American: XXII ), a plant biotechnology company that is a world leader in tobacco harm reduction,...

Load more

About 22nd Century Group Inc.

Our long-term focus is the research, development, licensing, manufacturing, and worldwide sales and distribution of our important products. 22nd Century Group’s proprietary genetic engineering technology and plant breeding expertise allow us to regulate the level of nicotine (and other nicotinic alkaloids) in the tobacco plant. As a result of our unique technology, we are able to grow tobacco with up to 97% less nicotine than conventional tobacco – as well as plants with relatively high nicotine levels. The applications for this technology are extraordinary; in independent clinical studies, our Very Low Nicotine Content (VLNC) tobacco has demonstrated remarkable efficacy as a smoking cessation aid. On the other hand, for smokers who do not wish to quit, our high nicotine tobacco enables us to produce a cigarette with what we believe is the world’s lowest tar-to-nicotine ratio.

We believe that the tobacco industry is at the beginning of a paradigm shift toward the development and commercialization of reduced-risk tobacco products which represent a significant step toward achieving the public health objective of harm reduction. Our 18 years of research and development on the tobacco plant, mainly on the nicotine biosynthetic pathway, uniquely positions us to become a major benefactor of this paradigm shift developing in the tobacco industry.


Henry Sicignano III
President & Chief Executive Officer
uan Sanchez Tamburri...
Vice President of Research and Development
Paul Rushton
Vice President of Plant Biotechnology
John T. Brodfuehrer
Chief Financial Officer
Thomas L. James
Vice President, General Counsel & Secretary
Michael Zercher
Vice President of Business Development
$ 1.94
Share volume:
261.236 K
Total value:
505.779 K
Market cap:
241.217 M